Search

Your search keyword '"Mehra N"' showing total 264 results
Start Over Author "Mehra N" Search Limiters Peer Reviewed
264 results on '"Mehra N"'

4. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Author

Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., and de Bono, J.S.

Published
2020
Full Text
View/download PDF

6. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

Author

van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., and Voest, E. E.

Published
2019
Full Text
View/download PDF

8. LBA72 Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Mehra, N., Van Wilpe, S., Westdorp, H., Kloots, I., Slootbeek, P., Brok, M. den, Franken, M., Coskuntürk, M., Bloemendal, H., Nagarajah, J., van Ipenburg, J., Kroeze, L., Ligtenberg, M., Schalken, J.A., and Gerritsen, W.R.

Subjects
*CASTRATION-resistant prostate cancer, *NIVOLUMAB, *IPILIMUMAB
Published
2024
Full Text
View/download PDF

19. 16th IHIW: Analysis of HLA Population Data, with updated results for 1996 to 2012 workshop data (AHPD project report)

Author

Riccio, M. E., Buhler, S., Nunes, J. M., Vangenot, C., Cuénod, M., Currat, M., Di, D., Andreani, M., Boldyreva, M., Chambers, G., Chernova, M., Chiaroni, J., Darke, C., Di Cristofaro, J., Dubois, V., Dunn, P., Edinur, H. A., Elamin, N., Eliaou, J.-F., Grubic, Z., Jaatinen, T., Kanga, U., Kervaire, B., Kolesar, L., Kunachiwa, W., Lokki, M. L., Mehra, N., Nicoloso, G., Paakkanen, R., Voniatis, Papaioannou D., Papasteriades, C., Poli, F., Richard, L., Alonso, Romón I., Slavčev, A., Sulcebe, G., Suslova, T., Testi, M., Tiercy, J.-M., Varnavidou, A., Vidan-Jeras, B., Wennerström, A., and Sanchez-Mazas, A.

Published
2013
Full Text
View/download PDF

49. 1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial.

Author

Mehra, N., Clarke, N.W., Armstrong, A.J., Oya, M., Shore, N.D., Procopio, G., Guedes, J.D.C., Arslan, C., Parnis, F., Brown, E., Schlürmann, F., Joung, J.Y., Sugimoto, M., Choi, Y.D., Castellano, D., Urun, Y., Hosius, C., Desai, C., Degboe, A., and Saad, F.

Subjects
*CASTRATION-resistant prostate cancer, *OLAPARIB, *PLACEBOS
Published
2023
Full Text
View/download PDF

50. 68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients.

Author

van Steenbergen, T. R. F., Smits, M., Scheenen, T. W. J., van Oort, I. M., Nagarajah, J., Rovers, M. M., Mehra, N., and Fütterer, J. J.

Subjects
DIFFUSION magnetic resonance imaging, PROSTATE cancer patients, PROSTATE biopsy, CASTRATION-resistant prostate cancer, ENDORECTAL ultrasonography, CONE beam computed tomography, BONE tumors, TREATMENT effectiveness, PILOT projects, RESEARCH evaluation, BONES, BIOPSY, OLIGOPEPTIDES, MAGNETIC resonance imaging, INTERVENTIONAL radiology, ETHYLENEDIAMINETETRAACETIC acid, COMPUTED tomography, PROSTATE tumors, LONGITUDINAL method
Abstract

Introduction: Precision medicine expands the treatment options for metastatic castration-resistant prostate cancer (mCRPC) by targeting druggable genetic aberrations. Aberrations can be identified following molecular analysis of metastatic tissue. Bone metastases, commonly present in mCRPC, hinder precision medicine due to a high proportion of biopsies with insufficient tumor cells for next-generation DNA sequencing. We aimed to investigate the feasibility of incorporating advanced target planning and needle guidance in bone biopsies and whether this procedure increases biopsy tumor yield and success rate of molecular analysis as compared to the current standards, utilizing only CT guidance.Materials and Methods: In a pilot study, ten mCRPC patients received 68Ga-prostate-specific membrane antigen (PSMA)-PET/CT and diffusion-weighted MRI as biopsy planning images. These datasets were fused for targeting metastatic lesions with high tumor densities. Biopsies were performed under cone-beam CT (CBCT) guidance. Feasibility of target planning and needle guidance was assessed, and success of molecular analysis and tumor yield were reported.Results: Fusion target planning and CBCT needle guidance were feasible. Nine out of ten biopsies contained prostate cancer cells, with a median of 39% and 40% tumor cells by two different sequencing techniques. Molecular analysis was successful in eight of ten patients (80%). This exceeds previous reports on CT-guided biopsies that ranged from 33 to 44%. In two patients, important druggable aberrations were found.Discussion: A biopsy procedure using advanced target planning and needle guidance is feasible and can increase the success rate of molecular analysis in bone metastases, thereby having the potential of improving treatment outcome for patients with mCRPC.Level Of Evidence: Level 4, case series. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results